Early Diagnosis of Oxaliplatin-induced Portal Hypertension
NCT ID: NCT04524650
Last Updated: 2020-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
370 participants
OBSERVATIONAL
2020-08-31
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxaliplatin-induced Portal Hypertension
NCT04524676
Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma
NCT03364530
Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma
NCT02548195
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
NCT06649474
Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury
NCT03069820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
stage 0
without liver function injury or splenomegaly
the level of vWF
the peripheral level of vWF
stage 1
occurrence of liver function injury (ALT or AST \> 2 ULN (upper limit of normal)
the level of vWF
the peripheral level of vWF
stage 2
occurrence of splenomegaly or reduced platelet count (\<150 X10\^9/L)
the level of vWF
the peripheral level of vWF
stage 3
occurrence of portal hypertension and/or gastroesophageal varices
the level of vWF
the peripheral level of vWF
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
the level of vWF
the peripheral level of vWF
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Had a history of oxaliplatin-based chemotherapy for the treatment of colorectal cancer surgery;
Exclusion Criteria
* With colorectal cancer required further anti-tumor treatment
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shiyao Chen
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gastroenterology and Hepatology
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Huang X, Li F, Wang L, Xiao M, Ni L, Jiang S, Ji Y, Zhang C, Zhang W, Wang J, Chen S. Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer. Endoscopy. 2020 Sep;52(9):727-735. doi: 10.1055/a-1157-8611. Epub 2020 May 7.
Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006 Nov 1;24(31):4983-90. doi: 10.1200/JCO.2006.05.8156.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PLAEGV-DIA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.